Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatment

Basit Öğe Kaydı
dc.authoridMungan, Semra/0000-0002-6469-5185;
dc.authorwosidMungan, Semra/AAR-3500-2021
dc.authorwosidEFENDI, HÜSNÜ/JUU-8107-2023
dc.contributor.authorTerzi, Murat
dc.contributor.authorHelvaci, Elif Merve
dc.contributor.authorSen, Sedat
dc.contributor.authorBoz, Cavit
dc.contributor.authorCilingir, Vedat
dc.contributor.authorAkcali, Aylin
dc.contributor.authorBeckmann, Yesim
dc.date.accessioned2024-06-12T11:00:08Z
dc.date.available2024-06-12T11:00:08Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of the first generic fingolimod active ingredient treatment in different centers across Turkey. Method: The first generic fingolimod efficacy and safety data of patients followed-up in 29 different clinical multiple sclerosis units in Turkey were analyzed retrospectively. Data regarding efficacy and safety of the patients were transferred to the data system both before the treatment and on the 6th, 12th and 24th month following the treatment. The data were analyzed using the IBM SPSS 20.00. P value of <0.05 was considered to be statistically significant. Results: A total of 508 multiple sclerosis patients, 331 of whom were women, were included in the study. Upon comparing the Expanded Disability Status values before and after the treatment, a significant decrease was observed, especially at month 6 and thereafter. Since bradycardia occurred in 11 of the patients (2.3%), the first dose had to be longer than 6 hours. During the observation of the first dose, no issues that could prevent the use of the drug occured. Side effects were seen in 49 (10.3%) patients during the course of fingolimod treatment. Respectively, the most frequent side effects were bradycardia, hypotension, headache, dizziness and tachycardia. Conclusion: The observed results regarding efficacy and safety were similar to clinical trial data in the literature and real life data in terms of the first equivalent with fingolimod active ingredient.en_US
dc.description.sponsorshipSANOVELen_US
dc.description.sponsorshipThanks to SANOVEL for funding the publication process.en_US
dc.identifier.doi10.29399/npa.28081
dc.identifier.endpage27en_US
dc.identifier.issn1300-0667
dc.identifier.issn1309-4866
dc.identifier.issue1en_US
dc.identifier.pmid36911568en_US
dc.identifier.scopus2-s2.0-85151017784en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage23en_US
dc.identifier.trdizinid1169769en_US
dc.identifier.urihttps://doi.org/10.29399/npa.28081
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1169769
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20703
dc.identifier.volume60en_US
dc.identifier.wosWOS:001190959500002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Neuropsychiatry Assoc-Turk Noropsikiyatri Dernegien_US
dc.relation.ispartofNoropsikiyatri Arsivi-Archives Of Neuropsychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEfficacyen_US
dc.subjectFingolimoden_US
dc.subjectMultiple Sclerosisen_US
dc.subjectSafetyen_US
dc.subjectOral Fingolimoden_US
dc.subjectInterferonen_US
dc.subjectTherapyen_US
dc.subjectTrialen_US
dc.titleClinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod Treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu